The latest updates from AFAR.

AFAR welcomes three New Board Members

Jul 13

AFAR welcomes three New Board Members View MoreBACK

At its June 13, 2017 meeting, the AFAR Board of Directors elected three new members: AnnaRosa Miele; Thomas Rando, MD, PhD; and Pol Vandenbroucke, MD, MSc, MBA, FFPM.

AnnaRosa Miele is the Chief Executive Officer and Co‐Founder of the Aristea Group and President of Confidustria Genova. Ms. Miele is a member of the Board of Directors of Confidustria Roma, the main association representing manufacturing and service companies in Italy. Ms. Miele is also Vice President of Federturismo, the national federation of the travel industry and tourism of Confidustria that represents the entire production chain of the tourism industry.

Thomas Rando, MD, PhD, is the Principal Investigator of the Thomas Rando Lab at Stanford University, where he is also the Director of the Glenn Center for the Biology of Aging, Deputy Director of the Stanford Center on Longevity, and a Professor in the Department of Neurology and Neurological Sciences. Additionally, he is the Director of the RR&D Center of Excellence / REAP and Chief of Neurology Science at the VA Palo Alto Health Care System. Dr. Rando is a 1999 Paul Beeson Career Development Scholar and a 2008 Glenn/AFAR Breakthroughs in Gerontology Award winner.

Pol Vandenbroucke, MD, MSc, MBA, FFPM, is the Vice President of Medical Strategy at Pfizer, where he is in charge of Global Patient Affairs, the Centers of Excellence for Pediatrics, Diversity in Clinical Trials and Healthy Aging, and the External Bioethics Advisory Panel. Before his current position, he was responsible for Medical Affairs of Pfizer’s Essential Health portfolio in North America, and he previously also led Clinical Development of all Pfizer compounds in Asia, Central and Eastern Europe, Latin America, and Africa‐ Middle East and of Pfizer’s Established Products globally.


For a complete list of AFAR's esteemed Board of Directors, please click here.